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ABSTRACT
Osteoporosis is a common age-related disorder and causes acute and long-term disability and economic cost. Many factors influence 
the accumulation of bone minerals, including heredity, diet, physical activity, gender, endocrine functions, and risk factors such as 
alcohol, drug abuse, some pharmacological drugs or cigarette smoking. The pathology of bone development during intrauterine life 
is a factor for osteoporosis. Moreover, the placental transfer of nutrients plays an important role in the building of bones of fetuses. 
The importance of maternal calcium intake and vitamin D status are highlighted in this review. Various environmental factors including 
nutrition state or maternal stress may affect the epigenetic state of a number of genes during fetal development of bones. Histone 
modifications as histone hypomethylation, histone hypermethylation, hypoacetylation, etc. are involved in chromatin remodeling, 
known to contribute to the epigenetic landscape of chromosomes, and play roles in both fetal bone development and osteoporosis. 
This review will give an overview of epigenetic modulation of bone development and placental transfer of nutrients. In addition, the 
data from animal and human studies support the role of epigenetic modulation of calcium and vitamin D in the pathogenesis of 
osteoporosis. We review the evidence suggesting that various genes are involved in regulation of osteoclast formation and differentia-
tion by osteoblasts and stem cells. Epigenetic changes in growth factors as well as cytokines play a rol in fetal bone development. 
On balance, the data suggest that there is a link between epigenetic changes in placental transfer of nutrients, including calcium and 
vitamin D, abnormal intrauterine bone development and pathogenesis of osteoporosis. 
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the strongest risk factors for osteoporotic fracture. Gene 
studies focused on BMD and documented the phenotype 
genetic correlation between BMD and osteoporotic 
fracture (Bass et al., 1998). Twin and family studies have 
shown that genetic factors play an important role in osteo-
porosis. Progress was made in: 1) heritability, osteoporosis 
and phenotype studies; 2) approaches for gene mapping 
and identification of gene mutations for osteoporosis; 
3) candidate gene association studies; 4) nutrients and 
osteoporosis; and 5) pharmacological drugs and pharma-
cogenomic studies for osteoporosis (Long et al., 2005). 
Epigenetic regulation of bones and osteoporosis is not 
well established. Moreover, the effect of nutrition status of 
the mother has been discussed for many years and several 
studies considered it as an environmental epigenetic 
factor that may play an important role during fetal devel-
opment. Nutrition, especially calcium intake influences 
the building of bones and prophylaxis of osteoporosis. 
Mother-offspring studies have demonstrated the role of 
some specific factors in early life, such as maternal body 
Introduction
Osteoporosis is a common age-related disorder. It is 
characterized by an excessively fragile skeleton and sus-
ceptibility to fractures (Harvey et al., 2008). Osteoporosis 
manifests clinically by fractures of the hip, vertebrae, dis-
tal forearm, etc. and the major cause of these fractures is 
low bone mass. It is well established that the skeletal size 
and density increase from early embryogenesis through 
intrauterine, infant, childhood and adult life. Various 
gene-mapping approaches have been applied to identify 
specific genes during all periods of bone development. 
Moreover, genes were detected for osteoporosis, involving 
largely low bone mineral density (BMD), which is one of 
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build, lifestyle and 25(OH)-vitamin D status of the mother, 
which might be important for bones of the fetus/neonate. 
In addition, the placenta plays a role in the nutrition status 
of the developing fetus. It is involved in the transport of 
nutrients and waste products between mother and fetus, 
being a source of many peptides and hormones that affect 
fetal development (Burton et al., 2001). The aim of the 
present review is to analyze published data in the field 
of epigenetic regulation of placental transfer of nutrients 
which may support better prophylaxis and treatment of 
osteoporosis. This review also summarizes the current 
knowledge on epigenetics of growth factors, cytokines 
and hormones in fetal bone development and their impact 
on osteoporosis. 
Basic genetic characteristics of bone 
development and osteoporosis
Regulatory regions of the human genome can be modified 
through epigenetic processes during prenatal life. Genetic 
s u s c e p t i b i l i t y  t o  o s t e o p o r o s i s  m a y  b e  b o t h  c o n t e x t  
dependent and developmentally regulated, and epigenetic 
mechanisms are the likely link between gene and envi-
ronment. Epigenetic changes may make individuals more 
likely to suffer from chronic diseases, as osteoporosis, 
when they reach adulthood. The modification of chro-
matin and DNA contributes to a larger well-documented 
process known as “programing”. 
Osteoporosis is one of various well documented 
“programing” chronic diseases (Tang et al., 2007). 
Chromosome 11q12-13 has been investigated for its link-
age to normal BMD variation (Koller et al., 2000; 2001). 
Reneland  et al.(2005) investigated more than 25,000 
single-nucleotide polymorphisms (SNPs) located within 
16,000 genes and established that variants in the gene 
encoding the phosphodiesterase 4D account for some of 
the genetic contribution to BMD variation in humans. The 
cause for osteoporosis pseudoglioma is a mutation in LRP5 
(low-density lipoprotein receptor-related protein), which 
is a member of Wnt family genes. Many of the known 
genes implicated by the 29 loci identified through GWAS 
participate in the Wnt/β-catenin signaling pathway. It is 
one of the signaling pathways through which members of 
the Wnt family can signal (e.g. GPR177, CTNNB1, LRP5, 
and SFRP4) and regulate bone development and bone loss. 
Xiong et al.(2009) reported the results from genome-wide 
association and follow-up replication studies which iden-
tified additional genes ADAMTS18 and TGFBR3 as bone 
mass candidate genes in different ethnic groups (Xiong et 
al., 2009). In addition, the RANKL/RANK/OPG pathway 
has also emerged from candidate gene and GWAS of 
BMD (e.g. TNFSF11 and TNFRSF11B). It is known that 
this pathway is involved in the regulation of osteoclast 
formation and differentiation by osteoblasts and stromal 
stem cells. The signaling system that involves receptor 
activation of nuclear factor-κB (RANK) by its ligand 
(RANKL), which is regulated by the soluble decoy recep-
tor osteoprotegerin (OPG), plays a role in the RANKL/
RANK/OPG pathway of gene control of fetal development 
of bones and osteoporosis. 
 The maintenance of calcium homeostasis by parathy-
roid hormone (PTH) is well established. Various animal 
and human studies have shown that the parathyroid gland 
secretes PTH in response to low serum calcium concen-
trations, which acts to normalize calcium levels through 
several mechanisms, including promotion of bone absorp-
tion (Nissenson et al., 2009). Some evidence has suggested 
that genes connected with PTH are strong candidate for 
genetic regulation of bone development and bone loss. In 
addition, several studies reported polymorphisms in genes 
in the PTH pathway. PTH, PTH-like hormone (PTHLH), 
and PTH1 receptor (PTHR1) are associated with either 
fracture risk or BMD. Their involvement in fetal bone 
development is not yet clear (Scillitani  et al, 2006; 
Vilariño-Güell et al., 2007; Gupta et al., 2008). Additional 
candidate for fetal bone development and osteoporosis 
is the gene COL1A1 Sp1 for type 1 collagen, which is a 
major protein of bone. The polymorphism of COL1A1 
Sp1 has been associated with osteoporotic fractures and 
BMD. Moreover, the studies suggest that COL1A1 Sp1 
plays a role in fetal bone development (Ralston, 2010). 
The vitamin D receptor (VDR) gene has been studied 
for its role in bone metabolism. The studies of Ensrud et 
al. (2009) evaluated the relation of VDR polymorphisms 
to bone loss. They found that low 25-hydroxyvitamin D 
levels have were associated with a higher rate of decline 
in total hip BMD in men. Several studies have reported 
associations between polymorphisms in VDR and cross-
sectional measures of BMD (Cooper et al., 1996). On 
balance, the data suggest that the gene for VDR receptor 
plays a role in fetal bone development. Figure 1 shows the 
role of VDR gene in regulation of various functions, as 
cell growth regulation, cell proliferation and differentia-
tion, immune functions, calcium homeostasis, etc., which 
are important for bones (Sundar and Rahman, 2011). In 
addition, various transcription factors that play roles in 
bone formation have been identified. For example, Sox9, 
Runx2, and Osterix are active in osteoblasts (Baek and 
Kim, 2011). In addition, the osteogenic genes such as 
ALP, type I collagen, osteocalcin, and bone sialoprotein 
(Bsp) are essential for osteoblast differentiation and bone 
formation (Matsubara et al., 2008). 
Epigenetics – link between genes and 
the environment in regulation of bone 
development and osteoporosis
Epigenetic changes are modifications to the DNA, which 
can be caused by various factors including environment, 
and which do not change the underlying sequence. 
Histone modifications, as histone hypomethylation, 
histone hypermethylation and hypoacetylation, etc., are 
involved in chromatin remodeling known to contribute 
to the epigenetic landscape of chromosomes. Epigenetic 
modifications can be passed down from the mother or 
father and can influence even the grandchild generation. 169
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They have the capacity to control whether a gene is turned 
on or off or how much message is processed. These 
changes to gene expression can lead to dramatic dif-
ferences in individual characteristics. Disruption of 
the epigenome is a fundamental mechanism in fetal 
development diseases. Epigenetic modifications, leading 
to dysregulation of critical genes controlling cell prolif-
eration, differentiation, and death of cells in fetal bones 
are not well established. However, epigenetics is a rapidly 
expanding field and various studies demonstrated the 
role of epigenetic modifications in bone development and 
osteoporosis. It has now been shown that the birth weight 
and childhood growth of 7,000 men and women born in 
Helsinki University Central Hospital during 1924–1933 
were linked to hospital discharge records for hip fracture 
(Coopere et al., 2001). The results from the Helsinki 
Cohort Study suggest that the growth in utero and early 
life of the offspring is associated with the actual risk of 
fracture. Twin studies also provided various opportunities 
to study the effect of the environment upon development, 
while controlling genetic variation (Javaid et al., 2004). 
In a study of 445 monozygotic and 966 dizygotic twins 
from the UK, at a mean age of 47 years, birth weight was 
found to positively predict BMC and BMD (Antoniades 
et al., 2003). The results suggest that there are epigenetic 
modifications in the regulation of bone development. 
Epigenetics refers to stable and heritable changes in gene 
expression that do not involve changes in DNA sequence. 
It is well established that histones stabilize DNA. Many 
environmental factors interact with genes through epigen-
etic mechanisms in human diseases, including osteopo-
rosis (Hunter, 2005). Gene-environment interactions are 
involved in fetal bone development and the changes may 
cause osteoporosis later in life. A specific genotype may 
result in a phenotype only in certain environments. For 
example, the interactions between the genome and fetal 
environment might establish basal levels of circulating 
growth hormone and contribute to accelerated bone loss. 
Many of these interactions occur primarily during early 
life (in fetuses and neonates). Several environmental fac-
tors have been shown to directly influence methylation 
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Figure 1. Epigenetic mechanism via modifi  cations of histone enzymes (deacetylases, demethylases, acetyltransferase or methyltransferase) 
plays a role in vitamin D3 (1α,25-dihydroxyvitamin D3)-mediated regulation of cellular and physiological functions.
Histone acetylation correlates with active gene transcription, and deacetylation associated with gene repression. Histone demethylases are 
involved in vitamin D3 receptor (VDR)-mediated transrepression. Gene repression of vitamin D3 and VDR aff  ects calcium homeostasis, immune 
function as well as metabolism of vitamin D3. Histone methyltransferase is involved in vitamin D3-mediated cell growth, cell cycle progres-
sion, cell proliferation and diff  erentiation, tumor suppression and immune function. VDR-mediated transcriptional activation plays a role in 
all the above vitamin D3-mediated cellular functions. Histone modifi  cations as histone hypomethylation, histone hypermethylation, histone 
hypoacetylation, etc. may aff  ect intrauterine growth regulation of bones. 170
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in some cases, epigenetic alterations are transmissible 
beyond a single generation (Jiang et al., 2004). Prenatal glu-
cocorticosteroids and neonatal behavioral manipulation 
(especially stress) promoted changes in histone acetylation 
and DNA methylation in a transcriptional factor binding 
site of glucocorticoid receptor (Weaver et al., 2004). The 
studies cited above on 3,639 men and 3,447 women born in 
Helsinki University Central Hospital supported the motion 
of epigenetic regulation of bone development. The results 
demonstrated that after adjustment for age and gender, 
there were two major determinants of hip fracture risk: 
tall maternal height and low rate of childhood growth. The 
data also showed that the hip fracture risk was elevated 
among babies born short. Fracture subjects were shorter 
at birth but of average height by the age of 7 years. These 
data suggest that the epigenetic mechanisms that respond 
to in utero or early life exposures play a critical role in 
growth/development of bones. The studies on animals 
also support the interactions between environmental 
factors and epigenetic mechanisms in bone development 
and osteoporosis. It was shown that alterations to the diet 
of pregnant animals can produce lasting changes in the 
offspring’s physiology and metabolism (Bateson, 2001). 
During mammalian development, signals about the nutri-
tional status transferred from the mother to her embryo or 
fetus either through the placenta or through lactation can 
affect the epigenetic reprograming in mammals (Morgan 
et al., 2005). This transfer of signals from mother to fetus 
may act to limit fetal growth, in preference to any genetic 
potential, and has been named ‘maternal constraint’ 
(Gluckman et al., 2008). Poor diet or limited nutrients for 
the fetus may cause various changes, including epigenetic 
modifications of histones/genes involved in bone develop-
ment. In addition, stressful stimuli and cortisol are major 
factors for epigenetic changes of fetal development. It was 
documented that the profiles of endogenous circulating 
cortisol and bone mineral density in healthy elderly men 
are dependent on fetal growth (Dennison et al., 1999). 
Moreover, a statistically significant positive association 
was found between characteristics of cortisol concen-
tration and femoral neck bone loss rate in 22 men, aged 
61–72 years, undergoing replicate bone density measure-
ments over a 4-year period. Their data also suggest that 
the endogenous cortisol profile of healthy elderly men is a 
determinant of their rate of fetal bone loss. 
On balance, the results from human and animal studies 
suggest that both nutrients and environmental factors as 
stress, smoking, drug abuse, radiation, etc. may play a role 
in epigenetic changes of intrauterine bone development.
Placental transfer of nutrients: epigenetic 
regulations and their role in fetal bone 
development and osteoporosis
DNA methylation, histone modifications and non-coding 
RNAs, affect gene expression in the placenta. This expres-
sion, including the important parent-of-origin-dependent 
gene expression resulting from genomic imprinting, plays a 
role in both fetal and placental development (Nelissen et al., 
2011). The study showed that the epigenetic of the placenta 
is a major factor of placental supply of nutrients to the fetus. 
Calcium and vitamin D are key nutrients likely to influence 
fetal bone development. The human fetus requires a total 
of 30 g of calcium for bone development, most of which 
is acquired during the third trimester via active transport 
across the placenta. Fetal calcium needs are primarily met 
by increased maternal intestinal calcium absorption dur-
ing pregnancy. The data indicated that very low maternal 
calcium intake may be a risk for lower bone mass in fetuses 
as well as in neonates. The importance of maternal vitamin 
D status has also been studied (Namgung and Tsang, 2003). 
It is well established that 1,25(OH)-vitamin D (the active 
form) mediates vitamin D effects first by binding to the 
vitamin D receptors (VDR), then by binding to the retinoic 
acid receptor (RXR), forming a heterodimer (Kimball et 
al., 2008). This heterodimer then acts upon vitamin D 
response elements in target genes, initiating gene tran-
scription by either up-regulating or down-regulating gene 
products. The expression of a placental calcium transporter 
(PMCA3) gene predicts neonatal whole-body BMC (Martin 
et al., 2007). The effects of maternal nutrition target the 
promoter region of specific genes. The VDR, the collagen 
type I alpha 1 gene (COLIA1) and estrogen receptor gene 
(ER) alpha have been most widely investigated and found 
to play a role in regulating BMD as well as targets for 
epigenetic regulation of placental transfer of nutrients 
(Williams and Spector, 2006). Epigenetic changes may 
associate with changes in DNA methylation of genes within 
or located near to vitamin D response elements. Modified 
expression of the genes encoding placental calcium 
transporters by epigenetic regulation may indicates data 
that maternal vitamin D status influences bone mineral 
homeostasis in the neonate. WNT2 promoter methylation 
in the human placenta was found to be associated with low 
birth weight percentile in the neonate (Ferreira et al., 2011). 
The DNA methylation differences identified in the 
promoter of the WNT2 gene were studied in an extended 
cohort of 170 samples. The results demonstrated that the 
WNT2 gene plays an important role in mouse placental 
development and confirmed its high expression in the 
human placenta. High WNT2 promoter methylation 
(WNT2PrMe) was found only in placental tissue and not 
in the cord blood of the fetus. The results also showed that 
WNT2 expression can be epigenetically down-regulated 
in the placenta by DNA methylation of its promoter and 
that high WNT2PrMe is an epigenetic variant associated 
with reduced fetal growth potential. Dysregulation of the 
genes led to the hypothesis that various epigenetic changes 
in the placenta responsible for nutrients transfer to the 
fetus played roles in abnormal fetal bone development and 
contributed to osteoporosis in the adults. Moreover, the 
results support the view that low birth weight as well as 
low BMD may result from maternal, fetal, placental and 
environmental factors.
In addition, various studies suggest that the epigenetic 
modulation of the HPA axis represents a second mechanism 
by which poor maternal nutrition as well as environment 171
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may cause epigenetic changes in bones of fetuses and neo-
nates. Protein restriction during mid and late pregnancy 
was found to be associated with reduced methylation of 
key CpG-rich islands in the promoter region of the gene 
for the glucocorticoid recpetor (GR) (Weaver et al., 2004). 
Further there was increased expression of the GR and 
DNA methylation, which is maintained through mitosis by 
DNA methyltransferase-1 (Dnmt1) activity. Moreover, the 
phenotype of an embryo can be modified by manipulation 
of DNA methyltransferase-1 (Dnmt1) expression by DNA 
methylation (Biniszkiewicz et al., 2002; Bird, 2001). In 
addition, several studies have confirmed that independent 
predictors of greater neonatal whole-body bone area and 
BMC include genes and their role in regulation of greater 
maternal birth weight, height and fat stores. Maternal 
activities such as smoking or drug abuse, dietary choices 
including calcium and vitamin D intake, and endocrine 
functions are factors for offspring bone development and 
may play roles in epigenetic mechanisms of placental trans-
port of nutrients (Dennison et al., 1999,2004; Javaid et al., 
2004,2005). Thus, for example, data that maternal smoking 
is statistically significantly associated with lower neonatal 
bone mass suggest a possible role of epigenetic changes.
Epigenetic pathways in bone development 
in animal and human models
Rat dietary protein restriction leads to altered Dnmt1 
expression. Dnmt1 expression in human umbilical cord 
predicts GR1-Ctotal (human glucocorticoid receptor 
1-Ctotal promoter) methylation. It was established that 
GR1-C total methylation status in human umbilical cord 
predicts GR expression. Induction of altered epigenetic 
regulation of the hepatic glucocorticoid receptor in the 
offspring of rats fed a protein-restricted diet during preg-
nancy suggests that reduced DNA methyltransferase-1 
expression is involved in impaired DNA methylation and 
changes in histone modifications (Lillycrop et al., 2007). 
Cooney et al. (2002) found that maternal methyl supple-
ments in mice affected epigenetic variation and DNA 
methylation of the offspring. In the agouti mouse mutant, 
maternal dietary folate supplementation at conception 
altered the expression of the imprinted agouti gene by 
altering the capacity for methylation (Cooney et al., 
2002). The relationship between poor nutrition in utero, 
weight in infancy and adult BMD has been replicated in 
population studies in the United States, Australia and 
Scandinavia (Cooper et al., 2006). These results suggest 
that genetic or epigenetic influences on bone development 
may be modified by poor nutrition in utero. Studies in 198 
children aged 9 years demonstrated that lower preconcep-
tion maternal weight, reduced maternal fat stores during 
late pregnancy, a history of maternal smoking during 
pregnancy and lower maternal social class were all associ-
ated with reduced whole-body BMC of the child at the age 
of 9 years (Javaid et al., 2006). Moreover, a lower ionized 
calcium concentration in umbilical venous serum may 
predict reduced fetus and neonate bone mass. Around 
31% of the mothers had insufficient and 18% had deficient 
circulating concentrations of 25(OH)-vitamin D during 
late pregnancy. Lower concentrations of serum 25(OH)-
vitamin D in mothers during late pregnancy were associ-
ated with reduced whole-body and lumbar spine BMC in 
children at the age of 9 years.
Growth factors (GF) play important roles in bone 
development (Winsloe et al., 2009). IGF-2 is known to 
be a key factor in human growth and development and 
it was found to be associated with epigenetic changes 
Interestingly, IGF-2 gene was hypomethylated, whereas 
interleukin-10, leptin, ATP-binding cassette A1 and 
maternally expressed 3 (meg 3) genes were hypermeth-
ylated. This study further supports the importance of 
investigating how early epigenetic modification of gene 
expression may influence long-term health and disease. 
IGF2 and H19, belonging to the same cluster of 
imprinted genes and regulated by ICR1, DMR2 and H19 
promoter elements, play a major role in fetal/placental 
growth. The epigenetic modulation of IGF2/H19 dur-
ing human development was marked in 60 normal and 
66 idiopathic IUGR (Intrauterine Growth Restriction) 
pregnancies. Embryonic (cord blood) and extraembry-
onic (placenta and umbilical cord) tissues were studied. 
Normal ICR1 methylation levels (approximately 50%) 
and H19 promoter/DMR2 hypomethylation were found 
in extra-embryonic tissues. In contrast, in embryonic 
samples the three loci displayed normal methylation val-
ues comparable to those in postnatal blood. Asymmetric 
allelic expression of H19 and IGF2 was reported as a com-
mon feature in pre- and post-natal tissues, independent of 
H19 promoter and DMR2 methylation levels. The study 
suggests that the gradient of global methylation, increas-
ing from extra-embryonic to embryonic and adult tissues, 
might play an important role in fetal/bone development. 
In addition, hypomethylation of H19 promoter and DMR2 
were not found to influence the expression pattern of 
IGF2 and H19 (Tabano et al., 2011). 
The role of cytokines in epigenetic regulation of bones 
is still not well established. There are data indicating that 
IL-6 genetic variation is prominently associated with hip 
BMD in late postmenopausal women without estrogen 
replacement therapy and/or with inadequate calcium 
intake (Ferrari et al., 2004). Growth factors interact with 
various cytokines in regulation of fetal development and 
further studies will determine whether the epigenetic 
modulations play roles in GF/cytokine relations.
Conclusion
Osteoporosis is a complex disease determined by genetic 
and environmental factors, as well as possible interactions 
among these factors. Epigenetic regulation of placental 
transfer of nutrients plays a role in both bone development 
and osteoporosis. Hypermethylation or hypomethylation, 
hypoacetylation or hyperacetylation of genes were found 
to regulate calcium, vitamin D, cytokines, growth factors, 
etc. in bone development. 172
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